Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sheikh Latif

Vascular Surgery Las Cruces, NM Doctor of Osteopathy

NPI 1144292251 CMS profile 908017

4351 E Lohman Ave Ste 202, Suite 201, Las Cruces, NM 88011

Open in the dashboard

General payments

$22,471

324 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sheikh Latif of Las Cruces, NM is reported in the CMS Open Payments database as having received $22,471 across 324 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,100 41
2024 General $10,067 51
2023 General $4,836 89
2022 General $2,078 73
2021 General $910 36
2020 General $3,362 27
2019 General $118 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sheikh Latif
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Sheikh Latif were reported at $1,100. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Sheikh Latif Vascular Surgery median Middle half National median
2019 $118 $796 $226–$2,363 $163
2020 $3,362 $348 $118–$1,110 $114
2021 $910 $471 $158–$1,421 $132
2022 $2,078 $725 $222–$2,183 $149
2023 $4,836 $836 $257–$2,440 $160
2024 $10,067 $909 $252–$2,619 $164
2025 $1,100 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Shockwave Medical, Inc $9,425 21 payments
  2. Medtronic, Inc. $3,971 73 payments
  3. Medtronic Vascular, Inc. $2,987 13 payments
  4. Philips Electronics North America Corporation $1,494 7 payments
  5. Tactile Systems Technology Inc $1,264 113 payments
  6. Boston Scientific Corporation $1,245 35 payments
  7. Silk Road Medical, Inc. $635 15 payments
  8. W. L. Gore & Associates, Inc. $492 14 payments
  9. Ethicon US, LLC $138 2 payments
  10. Bard Peripheral Vascular, Inc. $104 5 payments
  11. Other $716 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,667 301 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $6,600 2 payments
  3. Travel and Lodging $6,204 21 payments
Products named General payments · program years 2019–2025
  1. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $8,938 16 payments
  2. ENDURANT IIS $2,666 53 payments
  3. Valiant Captivia Aortic Stent Grafts $1,886 6 payments
  4. (BH4) IGT Devices Undivided $1,482 6 payments
  5. Flexitouch Plus $1,264 113 payments
  6. Valiant Captivia Aortic Stent Grafts $1,062 9 payments
  7. Endurant $951 6 payments
  8. ENROUTE Transcarotid Stent $605 14 payments
  9. ENROUTE Transcarotid Neuroprotection System $605 14 payments
  10. Entre Plus $565 55 payments
  11. Other $4,528 166 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

229

Median for Vascular Surgery: 122

Drug cost

$2,503

Median for Vascular Surgery: $14,135

Branded share of claims

55.5%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 127 $1,078
Prasugrel Hcl Generic 15 $985
Cephalexin Generic 52 $324
Atorvastatin Calcium Generic 11 $71
Diazepam Generic 24 $46

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$181,412

Medicare's payments for the services billed

Medicare patients

282

Average age 75

Services billed

1,238

148 women, 134 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Diabetes 40%
Ischemic heart disease 35%
Chronic kidney disease 32%
COPD 24%
Heart failure 21%
Atrial fibrillation 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

324 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record